In the validation cohort, patients in the CMTC-1 cohort were found to have significantly better clinical outcomes than the patients in the CMTC-2 and CMTC-3 groups as demonstrated in 2,239 breast cancers overall (Figure 2A), 1,058 non-adjuvant-treated cancers (Figure 2B) and 756 ER+ cancers (Figure 3B). This evidence concerns the gene ESR1 and cancer.